Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Children's Hospital of Wisconsin today announced the launch of an H1N1 influenza prevention campaign geared toward informing educators, parents, caregivers and children of all ages on the importance of practicing healthy habits this cold and flu season.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT’s Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA.
CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.
When the hitherto undetected A(H1N1) influenza attacked Mexico explosively in late April 2009, the world watched with critical attention as that country's leaders scrambled to manage the emerging public health crisis.
Dr. Bernard Kaminetsky, the medical director of MDVIP, a national network of affiliated primary care doctors focused on preventive care, recommends, “Talk to your primary care physician now about the flu, both seasonal and H1N1 flu. Your primary care doctor is the one who can best prepare you for the upcoming season with vaccinations as well as information specific to you.”
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special investigative report on CEL-SCI Corporation.
Business and healthcare leaders looking to fast-track preparedness for the H1N1 pandemic are gathering with infectious disease experts and Fortune 500 planners this month to determine how best to protect their employees and preserve their operations.
Recent findings that a single dose of an H1N1 (swine) flu vaccine offers protection against the virus and anticipation of vaccination programs starting earlier than predicted will increase the number of people worldwide with access to the vaccine and the likelihood health officials may be able to control the spread of the virus, Bloomberg reports.
The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.
Blue Cross and Blue Shield of Florida, Inc. (BCBSF) announces today its plans to offer coverage for the administration of the H1N1 vaccine to all members when it becomes commercially available to the public. The vaccine administration will be covered for members whose health care plans cover vaccines, as well as for those members whose plans currently do not include immunizations.
The American Lung Association is intensifying its seasonal influenza public education initiative to urge families to get vaccinated as soon as possible. The Faces of Influenza campaign aims to ensure Americans get immunized against seasonal influenza, which each year causes an estimated 36,000 deaths and over 226,000 hospitalizations from the virus and its related complications.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S.
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.
Small Business Administration Administrator Karen Mills and Department of Homeland Security Secretary Janet Napolitano today announced the availability of a preparedness guide designed to assist small businesses in planning for the possibility of an H1N1 flu outbreak this fall.
Research conducted at Texas A&M University casts doubts on the notion that El Ni-o has been getting stronger because of global warming and raises interesting questions about the relationship between El Ni-o and a severe flu pandemic 91 years ago. The findings are based on analysis of the 1918 El Ni-o, which the new research shows to be one of the strongest of the 20th century.
At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.
In an effort to help keep members healthy and flu-free this year, Independence Blue Cross (IBC) will offer coverage for the administration costs of the H1N1 (swine flu) vaccine when it becomes available. In addition, IBC will continue to cover seasonal flu vaccine.
As families return from summer travels and children head back to school, Emergency Medical Associates (EMA) is preparing for a potential resurgence in the swine flu virus (H1N1) this fall. By using business intelligence (BI) solutions from SAP AG (NYSE: SAP), EMA will continue to pinpoint the movement of swine flu and alert federal organizations such as the Centers for Disease Control and Prevention (CDC) as well as 21 different emergency medical departments to patterns of outbreak.
Health and Human Services Secretary Kathleen Sebelius said on Sunday that the H1N1 (swine) flu vaccine will be available in the U.S. earlier than previously anticipated, the Wall Street Journal reports. "We are on track to have an ample supply rolling out by mid-October, but we may have some early vaccine as early as the first full week in October. And we plan to get the vaccine rolling out the door as fast as it hits the production line," Sebelius said (Davis, 9/13).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.